← Back to Treatments
🏅 FDA Orphan Designation

Zynteglo

BETIBEGLOGENE AUTOTEMCEL

Manufacturer: Genetix Biotherapeutics Inc.

Indicated for:
Thalassemia

FDA-Approved Indications (1)

ZYNTEGLO is indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions.

Population: adult and pediatric patients

Indications & Usage

1 INDICATIONS AND USAGE ZYNTEGLO is indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions. ZYNTEGLO is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions. ( 1 )

💙 Support Programs

View all →
Zynteglo
Genetix Biotherapeutics Inc.
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.